- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03798431
MINDFUL-OBOT: Effect of Mindfulness on Opioid Use and Anxiety During Primary Care Buprenorphine Treatment
MINDFUL-OBOT Pilot: Effect of Mindfulness on Opioid Use and Anxiety During Primary Care Buprenorphine Treatment -- Pilot Study
Study Overview
Status
Intervention / Treatment
Detailed Description
The primary objective of this study is to conduct a single-arm pilot study in order to refine a Mindfulness-Based Intervention for the Opioid Use Disorder (OUD) treatment in primary care, called the Mindful Recovery OUD Care Continuum (M-ROCC). Study investigators will conduct qualitative interviews, assess opioid use, preliminary pre/post measures for participants participating in the pilot study. Additional aims of the pilot study is manual refinement and pilot testing assessment batteries to prepare for a multi-site RCT.
The study will focus on demonstrating feasibility and acceptability of the M-ROCC continuum.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Somerville, Massachusetts, United States, 02143
- Cambridge Health Alliance
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years or older
- Current CHA patient with a CHA primary care provider
- Diagnosis of opioid use disorder prescribed buprenorphine/naloxone
- Sufficient English fluency to understand procedures and questionnaires
- <90 days of complete abstinence from illicit opioids, cocaine, benzodiazepines, AND alcohol (excluding cannabis/nicotine)
- Ability to provide informed consent.
Exclusion Criteria:
- Psychosis
- Mania
- Thought disorder
- Schizophrenia or Schizoaffective disorder
- Acute suicidality with plan
- Cognitive inability as demonstrated by Montreal Cognitive Assessment (MOCA) <24 OR the inability to complete consent quiz and baseline assessments.
- Current participation in another CHA research study
- Expected hospitalization in next 6 months, including second and third trimester pregnancy at screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: M-ROCC
Mindful Recovery OUD Care Continuum (M-ROCC) builds on other mindfulness interventions for addictive disorders, but is specifically designed with the clinical needs of OUD patients on buprenorphine and logistic needs of primary care OBOT clinicians in mind.
It focuses on integration of mindfulness practice for living well through stress, anxiety, depression, pain and addiction recovery.
M-ROCC curriculum has three primary components, including a low-dose mindfulness phase, an intensive mindfulness training phase and then ongoing mindful recovery support.
|
After completion of the LDM group, participation in various levels is fluid based on patient motivation, choice, and readiness. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Likelihood of recommending program to a friend
Time Frame: Week 24
|
Percentage of participants who would recommend the program to a friend (score of 4 or 5 on a Likert scale (1-5))
|
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of weekly sessions attended
Time Frame: Week 24
|
Percentage of attendance out of 24 weekly group sessions during the 6 month study period.
|
Week 24
|
Anxiety PROMIS-SF 8a
Time Frame: Week 24
|
The Patient Reported Outcomes Measurement Information System - Anxiety Short Form 8a (PROMIS-ASF) is an 8-item scale used to assess patient-reported health status for anxiety.
PROMIS instruments are funded by the National Institutes of Health (NIH) and used to reliably and validly measure patient-reported outcomes for clinical research and practice.
Subjects are asked to rate their experience of the item in the past seven days on a 5-point scale from 1 (Never) to 5 (Always).
With use of the PROMIS Assessment Center Scoring Service, a T score is generated from subject responses.
A sample item includes "My worries overwhelmed me."
|
Week 24
|
Number of biochemically-confirmed illicit opioid abstinent weeks
Time Frame: Week 24
|
Number of 2-week time periods with no self-reported illicit opioid use and biochemically-confirmed abstinence from illicit opioid use during a 24-week period.
Urine toxicology will be administered every two weeks for 24 weeks and weekly self-report about illicit opioid use will be collected weekly.
|
Week 24
|
PROMIS-SF 8a (PROMIS-ASF) Pain Interference
Time Frame: Week 24
|
The PROMIS Pain Interference instruments measure the self-reported consequences of pain on relevant aspects of one's life.
This includes the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities.
Pain Interference also incorporates items probing sleep and enjoyment in life, though the item bank only contains one sleep item.
The Pain Interference short form is universal rather than disease-specific.
It assesses pain interference over the past seven days.
each question has five response options ranging in value from one to five (for pediatrics and parent proxy it is 0 to 4).
To find the total raw score for a short form with all questions answered, sum the values of the response to each question.
For example, for the adult 6-item form, the lowest possible raw score is 6; the highest possible raw score is 30.
A higher PROMIS T-score represents higher consequences of pain.
|
Week 24
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of biochemically-confirmed cocaine abstinent weeks
Time Frame: Week 24
|
Number of 2-week time periods with no self-reported cocaine use and biochemically-confirmed abstinence from cocaine use during a 24-week period.
|
Week 24
|
Brief Experiential Avoidance Questionnaire (BEAQ)
Time Frame: Week 24
|
The Brief Experiential Avoidance Questionnaire (BEAQ) is a 15-item scale developed to assess a broad range of experiential avoidance (EA) content.
Answers are based on a 6-point Likert scale.
Total score is sum of individual items (range is 15 - 90).
Higher score indicates higher levels of experiential avoidance.
|
Week 24
|
Patient Reported Outcomes Measurement Information System - Depression Short Form (PROMIS-DSF)
Time Frame: Week 24
|
The Patient Reported Outcomes Measurement Information System - Depression Short Form 8a (PROMIS-DSF) is an 8-item scale used to assess patient-reported health status for depression.
PROMIS instruments are funded by the National Institutes of Health (NIH) and used to reliably and validly measure patient-reported outcomes for clinical research and practice.
Participants are asked to rate their experience of the item in the past seven days on a 5-point scale from 1 (Never) to 5 (Always).
|
Week 24
|
Five Facet Mindfulness Questionnaire (FFMQ)
Time Frame: Week 24
|
is a 39-item scale that examines five factors that represent aspects of the current empirical conception of mindfulness.
These five facets include: "observing, describing, acting with awareness, non-judging of inner experience, and non-reactivity to inner experience."
An example item is "I pay attention to how my emotions affect my thoughts and behavior."
Subjects rate their degree of agreement with each of the items on a Likert-type scale ranging from 1 (Never or very rarely true) to 5 (Very often or always true), with higher scores indicating higher experience of mindfulness.
Total score is sum of all facets (range is 39 - 195).
Subscales range from 7 - 40.
|
Week 24
|
Difficulties in Emotion Regulation (DERS) Scale
Time Frame: Week 24
|
The DERS is a 36-item self-report scale designed to assess emotional dysregulation.
The scale assess 6 aspects of emotional dysregulation: non-acceptance of emotional responses ("When I'm upset, I become embarrassed for feeling that way"), difficulties engaging in goal directed behavior ("When I'm upset, I have difficulty thinking about anything else"), impulse control difficulties ("When I'm upset, I lose control over my behaviors"), lack of emotional awareness ("When I'm upset, I take time to figure out what I'm really feeling (reverse-scored)", limited access to emotion regulation strategies ("When I'm upset, it takes me a long time to feel better"), and lack of emotional clarity ("I have no idea how I am feeling").
Answers are selected from a 1-5 Likert scale.
Total score is sum of each subscale.
Subscales are scored by summing individual subscale items.
Total score ranges from 36 to 180 and subscale scores range from 5 to 40.
|
Week 24
|
Perceived Stress Scale (PSS) Scale
Time Frame: Week 24
|
The PSS Scale uses 14 items to measure the degree to which situations in life are stressful.
Items are designed to evaluate how overloaded, unpredictable, and uncontrollable one finds one's life.
Each item is scored on a 5 point Likert scale from 0 (Never) to 4 (Very often).
An example question is, "In the last month, how often have you felt difficulties were piling up so high that you could not overcome them?"
Positively stated items are reverse scored before all scale items are summed to yield a total score.
Total score ranges from 0 to 56.
|
Week 24
|
Self-Compassion Scale-Short Form (SCS-SF)
Time Frame: Week 24
|
The short-form Self-Compassion Scale (SCS-SF) is an abbreviated 12-item form of the original 26-item Self-Compassion Scale.
The scale is scored on a 5 point Likert scale (1 = Almost never; 5 = Almost always), and negative subscale items are reverse scored.
Total score is calculated by taking the mean of all scores and ranges from 1 to 5.
|
Week 24
|
Multidimensional Assessment of Interoceptive Awareness (MAIA)
Time Frame: Week 24
|
The Multidimensional Assessment of Interoceptive Awareness (MAIA) is a 32-item self-report scale designed to assess multiple aspects of interoception and interoceptive awareness.
The 6 point Likert scale (ranging from 0-5) assesses 8 aspects of interoceptive awareness: noticing, not-distracting, not-worrying, attention regulation, emotional awareness, self-regulation, body listening, and trusting.
Subscales are averaged, and a higher total score represents a better outcome.
Total average score can also be reported.
Total and subscale scores range from 0 to 5.
|
Week 24
|
Sustained Attention to Response Task (SART)
Time Frame: Week 24
|
Participants complete a computerized test measuring sustained attention and response inhibition.
They are asked to press a key in response to rapidly displayed integers (1-9) and withhold a response to a designated "no-go" integer.
|
Week 24
|
Hypothetical Delay Discounting Task (HDT)
Time Frame: Week 24
|
This is a brief delay discounting task performed on a computer that presents a series of 5 discrete choice questions between delayed larger reward and smaller sooner reward in dollars.
|
Week 24
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Zev Schuman-Olivier, MD, Study Principal Investigator
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHA-IRB-1094/08/18
- R21AT010125 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Lawson Health Research InstituteTerminated
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Federal Research Center of Fundamental and Translational...CompletedDepression Moderate | Depression MildRussian Federation
Clinical Trials on M-ROCC
-
Zimmer BiometBiomet France SARLTerminated
-
Cambridge Health AllianceNational Center for Complementary and Integrative Health (NCCIH)RecruitingDepression | Anxiety | Opioid-use Disorder | Stress Related DisorderUnited States
-
Zimmer BiometBiomet U.K. Ltd.Completed
-
Zimmer BiometActive, not recruitingRheumatoid Arthritis | Osteoarthritis, Knee | Arthrodesis | Traumatic Arthritis | Posttraumatic Deformity | Varus Deformity | Valgus Deformity | OsteotomyBelgium, Denmark, France, United Kingdom
-
Bercovy, Michel, M.D.Completed
-
HighField Biopharmaceuticals CorporationRecruiting
-
Fundació Institut de Recerca de l'Hospital de la...Sheba Medical Center; iMinds; Semmelweis University; AQuAS, Agència de Qualitat...CompletedSchizophreniaSpain, Hungary, Israel
-
Merck Sharp & Dohme LLCCompletedMeasles | Rubella | Mumps | VaricellaFrance, Italy
-
Kreiskrankenhaus DormagenCompletedFeasibility of Measurement of a Neuromuscular Block at the m. TrapeziusGermany
-
Samueli Institute for Information BiologyWilliam Beaumont Army Medical Center; Palmer Center for Chiropractic Research... and other collaboratorsUnknown